Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Genitourinary Cancer

Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial

Eur Urol

Grimm MO, Smith M, Hussain M, Saad F, Fizazi K, Littleton N, Paracha N, Srinivasan S, Verholen F, Tombal B

doi: 10.1016/j.eururo.2025.05.037

Genitourinary Cancer

Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial

J Clin Oncol

Saad F, Shore ND, Vjaters E, Olmos D, Littleton N, Liu A, Testa I, Mo M, Srinivasan S, Parambath Haresh K

doi: 10.1200/JCO.2025.43.5_suppl.15

Genitourinary Cancer

Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS

J Clin Oncol

Carles J, Tombal BF, Hussain MHA , Saad F, Fizazi K, Montesa Pino A, Méndez-Vidal MJ, Rodriguez-Vida A, Castellano D, Borrega P, Adorjan P, Moretones C, Dissanayake M, Smith MR

doi: 10.1200/JCO.2025.43.5_suppl.143

Breast Cancer

Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis

Adv Ther

Earla JR, Kurian AW, Kponee-Shovein K, Mahendran M, Song Y, Hua Q, Hilts A, Sun Y, Hirshfield KM, Robson M, Mejia JA

doi: 10.1007/s12325-024-03074-7

Genitourinary Cancer

Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Clin Cancer Res

Hage Chehade C, Graf RP, Ozay ZI, Gebrael G, Sayegh N, Li G, Maughan BL, Antonarakis ES, McKay RR, Agarwal N, Swami U

doi: 10.1158/1078-0432.CCR-25-1178

Genitourinary Cancer

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Prostate

Shimomura T, Otsuka N, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group

doi: 10.1002/pros.24885

Genitourinary Cancer

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Prostate

Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O

doi: 10.1002/pros.24855

COMMENTED

Breast Cancer

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer

★ 0 Recommended and commented by Dr Andreas Müller, Faculty Member

Clin Breast Cancer

Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.clbc.2025.05.015

Genitourinary Cancer

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

J Clin Oncol

Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP

doi: 10.1200/JCO-24-01798

Related content

Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial

Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial

Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS

Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis

Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial